Flare Therapeutics Presents Preclinical Data that Show Potential of Novel PPARG Inhibitors to Treat Urothelial Cancer at 2022 EORTC-NCI-AACR Symposium

First data showing durable in vivo tumor regression in urothelial cancer (UC) animal models Data highlight the potential for novel small molecule inhibitors of key transcription factors to

Related Keywords

United States ,Spain ,Barcelona ,Comunidad Autonoma De Cataluna ,Kostenloser Wertpapierhandel ,Amit Rakhit ,Sarah Mccabe ,Michelle Thaler ,Robert Sims ,Stern Investor Relations Inc ,Chief Scientific Officer ,Chief Executive Officer ,Third Rock Ventures ,Boxer Capital ,Nextech Invest ,Casdin Capital ,Invus Financial Advisors ,Eventide Asset ,Investor Relations ,Flare ,Herapeutics ,Presents ,Reclinical ,Data ,Show ,Potential ,Novel ,Sparg ,Inhibitors ,Treat ,Urothelial ,Dancer ,022 ,Hortc ,Racr ,Symposium ,